Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events

Subsequent Events

10.      Subsequent Events

On February 11, 2020, Fennec announced it had completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for PEDMARKTM (sodium thiosulfate anhydrous injection) for intravenous use.

Management has evaluated subsequent events through February 14, 2020, the date the financial statements were available to be issued and has concluded there are no additional events that would require adjustment to our disclosure in the statements.